Multi-omics in Severe Asthma From Olive Pollen Allergy (DUPITEOLE)
Multi-omics Study (Biological Therapy Followed by Immunotherapy) in Patients With Severe Asthma Due to Olive Pollen Allergy
Patients with severe olive pollen allergy exhibit characteristic sensitization profiles, marked by strong recognition of minor allergens like Ole e 7, and, more importantly, show poor clinical responses to pharmacological treatments and immunotherapy. Previous studies have revealed that these patients experience a permanent immunological dysfunction (notably, dysregulated effector T-cell function) leading to a systemic inflammatory state that persists beyond the pollen season.
The hypothesis is that short-term treatment (6 months) with Dupilumab can stabilize and reverse the inflammatory state in patients with severe olive pollen allergy (Project PI22/01737), enabling them to transition to conventional allergen immunotherapy.
This study aims to deepen our understanding of the mechanisms underlying this immunological stabilization through multi-omics profiling (metabolomics, proteomics, transcriptomics) to explain the resolution of inflammation. Specifically, the goal is to restore an effective regulatory T-cell response, allowing for allergen-specific immunotherapy, which can be administered for three years in routine clinical practice as the only treatment capable of altering the disease's progression.
Since immunotherapy relies on functional regulatory T-cell responses, this approach could validate a therapeutic strategy for these patients that modifies the disease long-term, breaking the cycle of chronic inflammation. This would reduce dependency on costly biologic treatments and significantly improve the quality of life.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Olive pollen (Olea europaea) is one of the leading causes of respiratory allergy in Mediterranean countries. Among the 14 olive pollen allergens identified to date, Ole e 1 is the major sensitizing allergen, whereas sensitization to Ole e 7 is strongly associated with a severe clinical phenotype in regions with intense olive cultivation, such as Córdoba (Spain). This phenotype is characterized by persistent airway inflammation, poor asthma control, and reduced response to allergen immunotherapy despite standard treatment.
Previous studies have demonstrated that severe olive pollen allergy is associated with a predominant type 2 inflammatory response, including increased frequencies of Th2 cells and type 2 innate lymphoid cells (ILC2), together with an imbalance between Th2 and Th1 immune responses. These immunological alterations are considered major contributors to persistent airway inflammation and reduced clinical efficacy of allergen immunotherapy.
Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα), inhibits signaling mediated by both IL-4 and IL-13 and has demonstrated efficacy in several type 2 inflammatory diseases, including severe asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. Short-term treatment with biological agents has also been shown to restore immune homeostasis and improve subsequent responses to allergen immunotherapy in selected allergic populations.
This observational study is conducted within the framework of the ISCIII-funded competitive research project PI22/01737. The objective is to characterize longitudinal immunological and molecular changes associated with allergen immunotherapy in severe olive pollen-induced allergic asthma and to evaluate the influence of previous short-term dupilumab treatment on these responses under routine clinical practice conditions.
Clinical follow-up will be complemented by comprehensive multi-omics analyses, including targeted serum metabolomics, serum proteomics, transcriptomic profiling, and peripheral T-cell immunophenotyping. These complementary approaches are intended to identify biological pathways associated with immune regulation, inflammatory activity, and the development of long-term immune tolerance during allergen immunotherapy.
Comparisons will be performed between individuals previously treated with a short course of dupilumab before initiation of allergen immunotherapy and individuals receiving conventional treatment without previous biological therapy. The integration of clinical, immunological, and multi-omics data is expected to improve the understanding of mechanisms associated with successful allergen immunotherapy and to identify candidate biomarkers related to treatment response and immune stabilization.
Because of the exploratory nature of the study and the complexity of the molecular analyses, the findings will primarily generate biological hypotheses and candidate biomarkers for validation in larger prospective cohorts. Identification of reproducible molecular signatures associated with successful immune modulation may contribute to the development of more personalized therapeutic strategies for severe olive pollen allergy and optimize the use of allergen immunotherapy in this population.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Cordoba
-
Córdoba, Cordoba, España, 14004
- Hospital Universitario Reina Sofia
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Patients ≥ 18 years old, residing in areas with high olive pollen exposure (exceeding 10,000 grains/m³ during the past five pollen seasons).
- Proven allergy to olive pollen with predominant or isolated sensitization to Ole e 7.
- Diagnosis of asthma that remains uncontrolled despite completing steps 5-6 of the GEMA guidelines during the olive pollen season.
- Controlled asthma with a forced expiratory volume in 1 second (FEV1) > 80% of the predicted normal value before starting subcutaneous immunotherapy (SCIT).
Exclusion criteria
- Having received allergen immunotherapy or biological treatment in the last 5 years.
- Pregnant women.
- Relevant comorbidity: cancer, myocardial infarction, severe immunological disorder .
- Contraindications contained in the official technical data sheet for Dupixent® (dupilumab).
- Contraindications of SCIT.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Dupilumab Pre-treated
Severe Phenotype Olive Pollen Allergy Patients Treated with Conventional Therapy plus Dupilumab
|
|
Conventional Treated
Severe Phenotype Olive Pollen Allergy Patients Treated with Conventional Therapy
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Targeted serum metabolomic profile
Periodo de tiempo: Baseline T0 (March 2024) and annually during the 3-year allergen immunotherapy period T1 (October 2024), T2, and T3, with additional assessments at 1 and 2 years after treatment completion (T4 and T5).
|
A targeted serum metabolomic profile associated with allergic inflammation will be assessed using a validated targeted metabolomics platform to evaluate changes induced by allergen immunotherapy.
|
Baseline T0 (March 2024) and annually during the 3-year allergen immunotherapy period T1 (October 2024), T2, and T3, with additional assessments at 1 and 2 years after treatment completion (T4 and T5).
|
|
Serum proteomic profile
Periodo de tiempo: Baseline (T0), T1 (October 2024), annually during the 3-year allergen immunotherapy (T2-T3), and 1 and 2 years after treatment completion (T4-T5).
|
Serum levels of proteins involved in allergic inflammation and immune regulation will be quantified to evaluate changes during allergen immunotherapy.
Protein quantification will be performed using a validated proximity extension assay (PEA).
|
Baseline (T0), T1 (October 2024), annually during the 3-year allergen immunotherapy (T2-T3), and 1 and 2 years after treatment completion (T4-T5).
|
|
Transcriptomic profile
Periodo de tiempo: Baseline (T0), T1 (October 2024), annually during the 3-year allergen immunotherapy (T2-T3), and 1 and 2 years after treatment completion (T4-T5).
|
Gene expression profiles associated with allergic inflammation and immune regulation will be assessed by RNA sequencing to evaluate changes during allergen immunotherapy.
|
Baseline (T0), T1 (October 2024), annually during the 3-year allergen immunotherapy (T2-T3), and 1 and 2 years after treatment completion (T4-T5).
|
|
Asthma Control Test (ACT) score
Periodo de tiempo: Every 4 weeks during the first 6 months (T0), annually during each olive pollen season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Asthma control will be assessed using the validated Asthma Control Test (ACT).
Changes in ACT score during allergen immunotherapy will be evaluated.
|
Every 4 weeks during the first 6 months (T0), annually during each olive pollen season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
|
Asthma symptom and medication score
Periodo de tiempo: Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Asthma symptoms and rescue medication use will be assessed using the predefined study score during each olive pollen season.
|
Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
|
Peripheral T-cell immunophenotype
Periodo de tiempo: Baseline (T0), T1 (October 2024), annually during the 3-year allergen immunotherapy (T2-T3), and 1 and 2 years after treatment completion (T4-T5).
|
Peripheral effector and regulatory T-cell subsets will be quantified by multiparametric flow cytometry to evaluate immunological changes during allergen immunotherapy.
|
Baseline (T0), T1 (October 2024), annually during the 3-year allergen immunotherapy (T2-T3), and 1 and 2 years after treatment completion (T4-T5).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Baseline demographic characteristics
Periodo de tiempo: Baseline (T0)
|
Baseline demographic characteristics, including age and sex, will be collected.
|
Baseline (T0)
|
|
Body mass index (BMI)
Periodo de tiempo: Baseline (T0) and annually at T1-T5.
|
Body mass index (BMI) will be calculated from height and weight recorded during follow-up.
Weight and height will be combined to report BMI in kg/m^2.
|
Baseline (T0) and annually at T1-T5.
|
|
Asthma control according to GEMA
Periodo de tiempo: Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Asthma control will be classified as controlled, partially controlled, or uncontrolled according to the GEMA guideline.
|
Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
|
Asthma treatment step according to GEMA
Periodo de tiempo: Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Asthma treatment will be classified according to the GEMA treatment step required to maintain disease control.
|
Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
|
Rhinoconjunctivitis symptom and medication score
Periodo de tiempo: Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Rhinoconjunctivitis symptoms and rescue medication use will be assessed using a predefined study score during each olive pollen season.
|
Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
|
Forced expiratory volume in one second (FEV1)
Periodo de tiempo: Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Forced expiratory volume in one second (FEV1) will be assessed by spirometry according to ATS/ERS recommendations.
|
Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
|
Mini Asthma Quality of Life Questionnaire (MiniAQLQ) score
Periodo de tiempo: Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Health-related quality of life will be assessed using the Mini Asthma Quality of Life Questionnaire (MiniAQLQ).
Scores range from 1 to 7, with higher scores indicating better quality of life.
|
Every 2 weeks during olive pollen season at T0, annually during each olive pollen (5 assessments) season the 3-year immunotherapy period (T1-T3), and at 1 and 2 years post-treatment (T4-T5).
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Berta Ruiz-Leon, MD., Ph.D., Hospital Universitario Reina Sofía de Córdoba
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- FCO-DPT-2024-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .